摘要
背景:将抗癌药物包含在生物相容性纳米颗粒载体中,由于可溶性循环游离药物的减少,降低了一般毒性并提高了临床治疗的疗效。 方法:此外,从废水中去除新出现的药物污染物是必须认真对待的。氮化硼 (BN) 是药物递送的一种选择,因为它具有许多令人惊讶的特性。在这里,制备了氮化硼纳米粒子,通过傅里叶变换红外光谱 (FT-IR) 和 X 射线衍射 (XRD) 进行表征,并用于递送美法仑抗癌药物。 结果:然后,进行密度泛函理论 (DFT) 计算以研究该药物通过熟悉的杂化泛函 B3LYP 和 B3PW91 在纯氮化硼富勒烯表面的吸附。此外,极化连续介质模型 (PCM) 计算表明 BN 在水中是稳定的。 结论:最后,在 ES-2 癌细胞上检查了 BN 纳米颗粒的体外细胞毒性和活力。该材料的抑制剂量 IC50 证实了可接受的细胞毒性和纳米颗粒影响 ES-2 癌细胞的平均生长。
关键词: 美法仑、吸附、DFT法、氮化硼富勒烯、抗卵巢癌药物、PCM。
Current Molecular Medicine
Title:Studying Adsorption and Cellular Toxicity of Boron Nitride Nanostructure versus Melphalan Anti-ovarian Cancer Drug
Volume: 21 Issue: 8
关键词: 美法仑、吸附、DFT法、氮化硼富勒烯、抗卵巢癌药物、PCM。
摘要:
Background: Inclusion of anticancer drugs into biocompatible nanoparticulate carriers decreases the general toxicity and improves the efficacy of clinical treatments due to the reduction of soluble circulating free drugs.
Methods: In addition, removal of emerging drug contaminants from wastewaters is a necessity that should be seriously attended. Boron nitride (BN) is a choice in drug delivery because of its many surprising properties. Here, boron nitride nanoparticles are prepared, characterized by Fourier-transform infrared spectroscopy (FT-IR) and x-ray diffraction (XRD) and used in the delivery of melphalan anti-cancer drug.
Results: Then, density functional theory (DFT) calculations are carried out to study the adsorption of this drug on the surface of pure boron nitride fullerene via familiar hybrid functionals B3LYP and B3PW91. In addition, the polarizable continuum model (PCM) calculations show that BN is stable in water.
Conclusion: Finally, the in vitro cellular toxicity and viability of BN nanoparticles was examined on ES-2 cancer cells. The inhibitory dose IC50 of the material confirmed acceptable cytotoxicity and nanoparticles affected the average growth of the ES-2 cancer cells.
Export Options
About this article
Cite this article as:
Studying Adsorption and Cellular Toxicity of Boron Nitride Nanostructure versus Melphalan Anti-ovarian Cancer Drug, Current Molecular Medicine 2021; 21 (8) . https://dx.doi.org/10.2174/1566524021666210111104428
DOI https://dx.doi.org/10.2174/1566524021666210111104428 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Trail Towards the Clinic
Current Drug Targets Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy
Current Cancer Drug Targets Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell
Current Pharmaceutical Biotechnology HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews Antitumour Antibiotics with Potent Activity Against Multidrug Resistant (MDR) Staphylococcus aureus: A New Approach to Targeting Resistant Bacteria
Medicinal Chemistry Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract
Current Drug Targets Chemical Constituents and Antitumor Mechanisms of <i>Artemisia</i>
Anti-Cancer Agents in Medicinal Chemistry Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer
Current Bioactive Compounds Evaluation of <sup>177</sup>Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
Current Radiopharmaceuticals Editorial [Hot topic:Targeted Alpha Particle Therapy (Guest Editors: Ganesan Vaidyanathan and Roy Larsen)]
Current Radiopharmaceuticals Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis
Current Drug Targets - Inflammation & Allergy